美托洛尔联合螺内酯治疗扩张型心肌病并心力衰竭的疗效分析

摘要

目的：探讨美托洛尔联合螺内酯治疗扩张型心肌病并心力衰竭的临床效果。方法：收治扩张型心肌病并心力衰竭患者108例，随机分为对照组和研究组，各54例，对照组予以常规抗心衰治疗，研究组在对照组基础上予以美托洛尔联合螺内酯治疗，比较两组治疗效果。结果：治疗后，研究组LVEF、LVFS、HR、SV、CO等指标改善均优于对照组(P＜0.05)，生存质量各项指标评分均明显高于对照组(P＜0.05)；研究组治疗期间出现心律失常21例(38.89%)明显少于对照组的40例(74.07%)，P＜0.05。结论：美托洛尔联合螺内酯治疗扩张型心肌病并心力衰竭的临床效果显著。%Objective:To explore the curative effect of metoprolol combined with spironolactone in treatment of dilated cardiomyopathy complicated with heart failure.Methods:108 patients with dilated cardiomyopathy complicated with heart failure were selected.They were randomly divided into the control group and the study group with 54 cases in each group.The control group was given conventional anti heart failure treatment.The study group was given metoprolol combined with spironolactone therapy on the basis of the control group.We compared the treatment effect of the two groups.Results:After treatment,in the study group,the improvement of LVEF,LVFS,HR,SV,CO and other indicators were better than that of the control group(P<0.05).The indicators of quality of life scores were significantly higher than that of control group(P<0.05).During the treatment,21 cases(38.89% ) with arrhythmia in study group were significantly less than 40 cases(74.07% ) of the control group,P<0.05. Conclusion:The curative effect of metoprolol combined with spironolactone in treatment of dilated cardiomyopathy complicated with heart failure was significant.